Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Denz

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Cellular Biochemistry|April 23, 2002
Characterization of a TM-4 type tropomyosin that is essential for myofibrillogenesis and contractile activity in embryonic hearts of the Mexican axolotlBelinda J Spinner, Robert W Zajdel, Matthew D McLean, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in VivoJames E Dowling, Marat Alimzhanov, Larry Bao, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in VivoJames E Dowling, Marat Alimzhanov, Larry Bao, et al.
Chemmedchem|April 4, 2017
Target Deconvolution Efforts on Wnt Pathway Screen Reveal Dual Modulation of Oxidative Phosphorylation and SERCA2Matias Casás-Selves, Andrew X Zhang, James E Dowling, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2018
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinasesLakshmaiah Gingipalli, Michael H Block, Larry Bao, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationJames E Dowling, Claudio Chuaqui, Timothy W Pontz, et al.
Chemmedchem|December 22, 2017
Structure-Based Design of Selective Noncovalent CDK12 InhibitorsJeffrey W Johannes, Christopher R Denz, Nancy Su, et al.
Cancer Cell|November 12, 2024
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversionRei Kudo, Anton Safonov, Catherine Jones, et al.
Cancer Cell|October 11, 2024
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversionRei Kudo, Anton Safonov, Catherine Jones, et al.
Journal of Medicinal Chemistry|September 3, 2025
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human KinomeAvipsa Ghosh, Afshan Ahmed, Konstantina Amoiradaki, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Cellular Biochemistry|April 23, 2002
Characterization of a TM-4 type tropomyosin that is essential for myofibrillogenesis and contractile activity in embryonic hearts of the Mexican axolotlBelinda J Spinner, Robert W Zajdel, Matthew D McLean, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in VivoJames E Dowling, Marat Alimzhanov, Larry Bao, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in VivoJames E Dowling, Marat Alimzhanov, Larry Bao, et al.
Chemmedchem|April 4, 2017
Target Deconvolution Efforts on Wnt Pathway Screen Reveal Dual Modulation of Oxidative Phosphorylation and SERCA2Matias Casás-Selves, Andrew X Zhang, James E Dowling, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2018
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinasesLakshmaiah Gingipalli, Michael H Block, Larry Bao, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationJames E Dowling, Claudio Chuaqui, Timothy W Pontz, et al.
Chemmedchem|December 22, 2017
Structure-Based Design of Selective Noncovalent CDK12 InhibitorsJeffrey W Johannes, Christopher R Denz, Nancy Su, et al.
Cancer Cell|November 12, 2024
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversionRei Kudo, Anton Safonov, Catherine Jones, et al.
Cancer Cell|October 11, 2024
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversionRei Kudo, Anton Safonov, Catherine Jones, et al.
Journal of Medicinal Chemistry|September 3, 2025
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human KinomeAvipsa Ghosh, Afshan Ahmed, Konstantina Amoiradaki, et al.
Pageof 2